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1. Introduction 
1.1 Synopsis 
A wide range of orthopedic, cardiothoracic, neurological, and maxillofacial procedures 
requires that the bone be cut or resected, either to operate on the osseous tissue itself or to 
gain access to other organs. As any living tissue, bone bleeds when cut or fractured, and 
to reduce the risk of post-operative complications, bone bleeding needs to be managed 
during surgery. The present chapter examines the relationship between the management 
of bleeding and post-operative complications, and, in particular, the impact of bone 
hemostasis materials on the incidence of post-operative infection of soft tissue and 
osteomyelitis. Section 2, “Bone Surgery and Management of Bleeding,” opens the 
argument by discussing the increase in the number of procedures involving the bone, the 
importance of effective bone and soft tissue hemostasis for assuring positive surgical 
outcome, and the surgeons’ reliance on bone wax composed of beeswax, despite serious 
complications associated with its use. Section 3, “Surgical Site Infections and 
Osteomyelitis,” focuses on the growing incidents of surgical site infections and post-
operative osteomyelitis, and the added risk posed by the presence of antibiotic-resistant 
bacteria. Section 4, “Antibiotic Prophylaxis,” discusses systemic SSI prevention and the 
use and effectiveness of topical antibiotic prophylaxis. “Systemic and Perioperative Risk 
Factors for Postoperative Osteomyelitis,” in Section 5 analyses infection risk factors and 
predictors of complications following cardiac, orthopedic, and neurosurgical procedures. 
It focuses on excessive bleeding and subsequent extended duration of surgical procedure 
as infection risk factors, and the importance of effective bone hemostasis in minimizing 
the risk. Section 6, “Bone Wax as a Modifiable Risk Factor for Osteomyelitis, Chronic 
Inflammation, and Inhibited Bone Healing,” discusses a body of research linking the use 
of traditional bone wax, most widely used bone hemostasis material, to inhibition of bone 
healing, inflammation, and increased soft tissue infection and osteomyelitis rates. The use 
of bone wax – and the choice of bone hemostasis material in general – remains a largely 
overlooked modifiable risk factor for osteomyelitis and other post-operative infections. 
Surgeons are often unaware of the post-operative complications attributed to the use of  
bone wax and unfamiliar with the range of alternatives available for bone hemostasis. 
Section 7, “Alternative Bone Hemostasis Materials and Methods,” elaborates on a wide 
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range of existing alternatives to bone wax, including synthetic topical bone hemostats 
which replicate the handling of traditional bone wax without its risks. The section also 
reviews studies of topical bone hemostasis materials and offers an analysis of existing 
comparative studies of new bone formation and healing, rate of infection, osteomyelitis, 
and the materials’ effectiveness as bone hemostats, underscoring the role the surgeons’ 
choice of bone hemostasis material can play in the promotion and prevention of post-
operative complications. Polymer bone hemostats emerge in the studies as materials that 
do not inhibit bone healing and do not promote osteomyelitis or inflammation. 
“Redefining the Management of Bone Bleeding: Osteomyelitis, Bone Healing, and Topical 
Therapeutics” is the focus of Section 8, which explores the potential of combining topical 
bone hemostasis materials with therapeutics -- antibiotics or bone grafts – a combination 
which would make the management of bone bleeding an aspect of a larger surgical 
procedure and an important step in prevention and treatment of osteomyelitis. Section 9 
concludes that a better understanding by the surgeons of the adverse effects of bone wax 
and of the overall impact bone hemostasis technique and material choice have on the 
clinical outcome may help reduce infections and the rate of osteomyelitis as well as 
broaden the repertoire of medical tools available to operating physicians and improve 
outcomes across surgical procedures. 
1.2 Key terms 
Osteomyelitis; post-operative infection; bone wax; modifiable risk factor for infection; 
topical bone hemostasis; topical therapeutics; alternatives to bone wax;  bone surgery. 
2. Bone surgery and management of bleeding 
2.1 Bone bleeding in surgery 
Bone, whether sternal, spinal, or any other, is a living tissue, and any invasive procedure 
involving the cutting of the bone requires management of bone bleeding, both to reduce 
blood loss and hematoma formation for the patient and to ensure good visibility of the 
operating site for the surgeon. To optimize surgical success and patient outcome, it is 
important to maintain a fine balance between bleeding and clotting during surgery, so that 
blood continues to flow to the tissues at the surgical site, but its loss is not excessive 
(Samudrala, 2008).1  Uncontrolled continuous bleeding can obscure the surgical field, 
prolong operating time, increase the risk of physiologic complications, and expose the 
patient to additional problems associated with blood transfusion. For patients undergoing 
elective coronary artery bypass graft surgery, allogeneic blood transfusion has been shown 
to double the risk of infection (Rogers et al., 2009).2 
                                                                          
1 Samudrala, S. “Topical Hemostatic Agents in Surgery: A Surgeon’s Perspective.”  AORN Journal, 2008. 
Supplement: Intraoperative Bleeding and Hemostasis in Surgical Procedures. vol. 88, no 3: p. S2-11 
2 In a cohort study of 24,789 Medicare beneficiaries who received coronary artery bypass graft 
surgery, allogeneic blood transfusion increased the odds of in-hospital infection 2.0-fold, in-hospital 
mortality 4.7-fold, 30-day readmission 1.4-fold, and 30-day mortality 2.9-fold. See: Mary AM Rogers, 
Neil Blumberg, Sanjay Saint, Kenneth M Langa, and Brahmajee K Nallamothu. “Hospital variation in 
transfusion and infection after cardiac surgery: a cohort study.” BMC Medicine 2009, 
7:37doi:10.1186/1741-7015-7-37 
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2.2 Growing number of surgeries involving the osseous tissue  
Bone tissue is one of the most frequently transplanted tissues, second only to blood 
(Giannoudis, 2005).3 It is increasingly needed across surgical fields as bone grafts are used 
to fill defects caused by trauma, infection of soft tissue and osteomyelitis, tumor resection, 
reconstruction of congenital malformations, and age-related decrease of bone mass. Over 
1.8 million bone graft procedures were reported in 2006, a number that has risen 
exponentially since 1990 and that continues to grow with the ageing of population 
(Hladki, 2006). 4  
Other surgical procedures performed on the bone have also been on the rise in the United 
States. The number of joint arthroplasties currently exceeds 1,000,000 procedures per year 
(AAOS).5 According to Centers for Disease Control and Prevention, there were 2,476,000 
orthopedic and spinal surgeries in 2007, the last year for which data are available. Spine 
fusions and excisions of intervertebral discs accounted for 659,000 in-patient operations on 
the skeletal system while median sternotomies were performed 1,022,000 times in the same 
period in order to gain access to the heart in angioplasty and coronary artery bypass graft 
procedures (CDC).6 
2.3 Management of bleeding and successful surgical outcome 
During a surgical procedure involving bone, surgical technique and the management of 
bone bleeding are important factors in determining a successful outcome. When bone is cut, 
irrigation is used to prevent heat formation and thermal injury to the bone. Cut surfaces are 
kept moist to avoid desiccation, and efforts are made to preserve the blood supply. The 
blood flow through cortical bone occurs through the relatively small vascular channels of 
the Haversian system. Bone bleeding originates predominantly in the cancellous bone. The 
hematopoietic elements are contained within a honeycombed network of vascular channels 
and can be a source of profuse bleeding. Electrocautery, which is useful in soft tissue 
hemostasis, functions primarily to collapse and seal blood vessels. To be effective in 
controlling bone bleeding, it would have to generate sufficient heat to create a coagulum 
that would physically block vascular channels – the thermal injury to the adjacent bone 
would be of such magnitude, that any hemostatic benefit would be offset by the resultant 
bone necrosis. 
2.4 Effective bone hemostasis 
The most immediate and effective way to stem bone bleeding is to physically block the open 
vascular channels, a process known as tamponade. Until the recent introduction of soluble 
                                                                          
3 Giannoudis, P.V., H. Dinopoulos, and E. Tsiridis, “Bone substitutes: an update.” Injury, 2005. 36 Suppl 
3: p. S20-7 
4 Hladki, W., L. Brongel, and J. Lorkowski, “Injuries in the elderly patients.” Przegląd Lekarski, 2006. 63 
Suppl 5: p. 1-4.0 
5 AAOS Medical Letter: “Antibiotic Prophylaxis for Bacteremia in Patients with Joint Replacements.”February 
2009, Revised June 2010. http://www.aaos.org/about/papers/advistmt/1033.asp 
6 Source: National Hospital Discharge Survey: 2007 Summary, table 8. Centers for Disease Control and 
Prevention http://www.cdc.gov/nchs/fastats/insurg.htm accessed July 31, 2011. 
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synthetic polymers, the only widely available tamponade material was bone wax, a beeswax 
based blend. Bone wax sticks to bone blocking the vascular channels, providing immediate 
bone hemostasis. Although inexpensive and easy to use, bone wax has a number of 
troublesome side effects. Once applied to bone, bone wax remains at the site indefinitely. 
Bone wax is known to interfere with bone healing, elicit chronic inflammatory reactions, and 
increase infection rates (Allison, 1994; Armstrong et al., 2010; Chun, 1988; Finn, 1992; 
Johnson, 1981; Nelson, 1990; Gibbs, 2004; Sawan et al., 2010; Schonauer et al. 2004; Solheim 
et al., 1992; Wellisz et al., 2006, 2008a, 2008b).7 And yet, the use of bone wax remains 
relatively widespread, and surgeons are often unaware of the complications surrounding its 
application. In fact, the effect of bone hemostasis materials in general, not just bone wax, on 
post-operative infection remains largely neglected in the current professional literature. By 
and large, existing infection studies in orthopedic, cardiac, and neurological surgery do not 
mention the type of bone hemostasis materials used in any given trial, overlooking the fact 
that bone hemostasis materials are in themselves modifiable risk factors, both for soft tissue 
infection and for osteomyelitis. 
3. Surgical site infections and osteomyelitis 
3.1 Risk of surgical site infection 
Surgical site infections (SSI) account for nearly 25% of all hospital infections in the United 
States. All tissues, soft and osseous, are susceptible to post-operative complications; an 
increasing number of infections are methicillin-resistant, making treatment more difficult 
and effective prophylaxis more urgent (Georgia Epidemiology Report, 2004; Kronemyer, 
2004; Styers et al, 2006).8 Although technological advances and focus on prevention lower 
                                                                          
7 For detailed discussions of various complications related to the use of bone wax, see: Allison RT. “Foreign 
body reactions and an associated histological artifact due to bonewax.” Br. J. Biomed. Sci. 1994; 51:14-17. 
Armstrong et al. BMC Surgery 2010, 10:37 http://www.biomedcentral.com/1471-2482/10/37; Chun PKC, 
Virmani R, Mason TE, Johnson F. “Bone wax granuloma causing saphenous vein thrombosis.” Am. Heart J. 
1988; 115:1310-1313. Finn MD, Schow SR, Scneiderman ED. “Osseous regeneration in the presence of four 
common hemostatic agents.” J. Oral Maxillofac. Surg. 1992;50:608-612. Gibbs L, Kakis A, Weinstein P, Conte 
J. “Bone wax as a risk factor for surgical site infection following neurospinal surgery.” Infect. Control Hosp. 
Epidemiol. 2004; 25:346-348. Johnson P, Fromm D. “Effects of bone wax on bacterial clearance.” Surgery 
1981; 89:206-209. Nelson DR, Buxton TB, Luu QN, Rissing JP. “The promotional effect of bone wax on 
experimental Staphylococcus Aureus osteomyelitis.” J. Thorac. Cardiovasc. Surg. 1990; 99:977-980. Sawan A, 
Elhawary Y, Zaghlool Amer M, & Abdel Rahman M. “Controversial Role of Two Different Local 
Haemostatic Agents on Bone Healing.” Journal of American Science, 2010; 6(12):155-163]. (ISSN: 1545-1003); 
Schonauer, C., E. Tessitore, et al. (2004). “The use of local agents: bone wax, gelatin, collagen, oxidized 
cellulose.” Eur Spine J 13 Suppl 1: S89-96. Solheim E, Pinholt EM, Bang G, Sudmann E. “Effect of local 
hemostatics on bone induction in rats: a comparative study of bone wax, fibrin-collagen paste, and 
bioerodible polyorthoester with and without gentamicin.” J Biomed Mater Res. 1992 Jun;26(6):791-800. 
Wellisz T, Armstrong JK, Cambridge J, Fisher TC: “Ostene, a new water-soluble bone hemostasis agent.” J 
Craniofac Surg 17: 420-425, 2006. Wellisz T, An YH, Wen X, Kang Q, Hill CM, Armstrong JK. “Infection 
rates and healing using bone wax and a soluble polymer material.” Clin Orthop Relat Res 2008; 466:481-6. 
Wellisz T, Armstrong JK, Cambridge J, et al. “The effects of a soluble polymer and bone wax on sternal 
healing in an animal model.” Ann Thorac Surg 2008; 85:1776-80;  
8 Georgia Epidemiology Report (GER). Community-associated Methicillin Resistant Staphylococcus aureus 
(MRSA). June 2004;20:1-4. Kronemyer B. MRSA incidence on the rise. Infectious Disease News. May 1, 
2004. http://www.infectiousdiseasenews.com/article/33489.aspx. Accessed August 5, 2011; Styers D, 
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the risk of post-operative infection, when the complication does occur, the human and 
financial cost is extremely high. Patients who develop surgical site infections (SSI) are 60% 
more likely to spend time in an intensive care unit; they are five times more likely to be 
readmitted to the hospital; they have three times the length of hospital stay; and their mortality 
rate is five times that of inpatients without wound infections (CDC, 2011; Noskin et al., 2005).9 
Infections caused by resistant organisms exact an even higher toll on individual patients and 
healthcare system (Carmeli et al., 1999; Cosgrove et al., 2002; Kronemyer, 2004).10 
3.2 Risk of bone infection in cardiac, orthopedic, and neurological surgery 
In cardiac surgery, infections of median sternotomy wounds are a rare but grave 
complication. Mediastinitis occurs in 0.3–5% of cases, but it is associated with a mortality 
rate between 14 and 47% (Losanoff et al., 2002).11 Left untreated, these infections can extend 
to aortic and cardiac suture lines, prosthetic grafts, and intracardiac prostheses (Pairolero & 
Arnold, 1986).12 The added financial cost of treating mediastinitis to an individual 
institution has been reported as high as $500,000 USD (Lee et. al, 2009).13  In orthopedic 
surgery, approximately 7% of total joint arthroplasties performed annually in the US are 
revision procedures – the result of deep infections of total joint replacements and the 
consequent failure of the initial operations (CDC; AAOS, 2010). In neurosurgery, 
postoperative wound infection following intracranial surgery has a reported incidence 
ranging from 1% to 8%, with significant geographic variations in Europe and North 
America, and it carries a high risk of morbidity and mortality if not aggressively treated.14 
4. Antibiotic prophylaxis 
4.1 SSI Prevention 
While treatment of Surgical Site Infections (SSI) is essential, the focus in the medical 
community remains on preventing the complications from occurring. There is much clinical 
                                                                          
Sheehan DJ, Hogan P, et al. “Laboratory-based surveillance of current antimicrobial resistance patterns 
and trends among Staphylococcus aureus: 2005 status in the United States.” Ann Clin Microbiol 
Antimicrob. 2006. 5:2 
9 Sources: Centers for Disease Control and Prevention (CDC). National Center for Health Statistics. 
Leading causes of Death. http://www.cdc.gov/nchs/fastats/lcod.htm. Accessed July 30, 2011; for 
complications and associated cost of infections, see: Gary A Noskin, Robert J. Rubin, et al. “The Burden 
of Staphylococcus aureus Infections on Hospitals in the United States.” Arch Intern. Med. 2005;165:1756-
1761.  
10 See for example: Carmeli Y, Troillet N, Karchmer AW, et al. “Health and economic outcomes of 
antibiotic resistance in Pseudomonas aeruginosa.” Arch Intern Med. 1999;159:1127-1132; Cosgrove SE et 
al. “Health and economic outcomes of the emergence of third-generation cephalosporin resistance in 
Enterobacter species.” Arch Intern Med. 2002. 162:185-190; Kronemyer, 2004 
11 Julian E. Losanoff, Bruce W. Richman, James W. Jones. “Disruption and infection of median 
sternotomy: a comprehensive review.” Eur J Cardiothorac Surg 2002;21:831-839 
12 Pairolero PC & Arnold PG “Management of Infected Median Sternotomy Wounds.” Ann Thorac Surg, 
1986; 42:1-2. DOI: 10.1016/S0003-4975(10)61822-X 
13 Lee JC, Raman J, Song DH. “Primary sternal closure with titanium plate fixation: plastic surgery 
effecting a paradigm shift.” Plast Reconstr Surg 2010;125:1720-4. 
14 McClelland, S., “Postoperative intracranial neurosurgery infection rates in North America versus 
Europe: A systematic analysis.” Am J Infect Control 2008; 36:570-3 
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evidence that antibiotics used preventively significantly reduce the occurrence of SSI across 
surgical fields. As a result, antimicrobial prophylaxis is becoming the standard of care. The 
American Academy of Orthopedic Surgeons (AAOS), the American Academy of 
Neurosurgeons (AANS), The Society of Thoracic Surgeons (STS), and the North American 
Spine Society (NASS) currently recommend perioperative use of antibiotics to lower the risk 
of infection of soft tissue and the incidence of post-operative osteomyelitis in spinal 
procedures, neurosurgery, orthopedic and cardiac surgery. There is a growing consensus 
that patients in high-risk groups, those undergoing procedures associated with high 
infection rates, involving implantation of grafts or prosthetic material, or surgeries in which 
the consequences of infection are serious, should receive systemic perioperative antibiotics 
targeting the most likely organisms (AAOS, 2010; Edwards et al., 2006; Engelman et al., 
2007; Watters et al., 2007). 15 
4.2 Systemic antibiotic prophylaxis 
The value of systemic prophylaxis depends critically upon the activity of the antibiotic 
towards the causative organisms. In cardiac procedures, peri-operative intravenous 
antibiotic prophylaxis was shown to reduce the incidence of SWIs by up to 80% compared to 
placebo (Kreter & Woods, 1992).16 In neurosurgical and orthopedic procedures, wound 
infection rates decreased by 63% with IV antibiotic prophylaxis. But IV prophylaxis tends to 
target infections caused by gram-negative bacteria, and while S. aureus and S. epidermidis are 
the most common causes of SSI, they are increasingly methicillin resistant (CDC, 2009).17  
Vancomycin is often the only effective antibiotic available for treatment of surgical site 
infection caused by methicillin-resistant gram-positive organisms. Since broad systemic use 
of Vancomycin for prophylaxis is discouraged for epidemiological reasons, local delivery of 
antibiotic directly to the surgical site may be an alternative or an effective adjunct to 
systemic SSI prophylaxis. 
4.3 Use of topical antibiotic prophylaxis in surgery 
While systemic use of antibiotic prophylaxis is generally recommended and practiced, there 
is evidence that local application directly to the the surgical site is effective at reducing the 
incidence of post-operative infection of both soft tissue and osteomyelitis in cardiac, spinal, 
orthopedic and neuro-surgical procedures. Topical application of Vancomycin powder to 
the sternal edges has been shown to reduce SWI following cardiac surgery (Vander et al., 
                                                                          
15 For detailed practice guidelines, see: Edwards et al. “The STS Practice Guideline Series: Antibiotic 
Prophylaxis in Cardiac Surgery, Part I: Duration.” Annals of Thoracic Surgery 81(1): 397–404 (2006); 
Engelman R et al. “The STS Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: 
Antibiotic Choice.” Annals of Thoracic Surgery 2007; 83: 1569-1576; Watters WC III, MD et al. North 
American Spine Society Evidence-Based Clinical Guidelines for Multidisciplinary Spine Care, 2007. 
AAOS Information Statement “Antibiotic Prophylaxis for Bacteremia in Patients with Joint 
Replacements.” February 2009, revised June 2010. http://www.aaos.org/about/papers/advistmt/ 
1033.asp retrieved July 30, 2011; 
16 Kreter B, Woods M. “Antibiotic prophylaxis for cardiothoracic operations. Meta-analysis of thirty 
years of clinical trials.” J Thorac Cardiovasc Surg 1992;104(3):590-9 
17 Centers for Disease Control and Prevention (CDC). Prevent antimicrobial resistance in healthcare 
settings. http://www.cdc.gov/drugresistance/healthcare/problem.htm. Accessed September 27, 2009. 
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1989).18 There is also anecdotal evidence that cardiothoracic surgeons in the United States 
commonly consider topical application of Vancomycin to be effective in preventing infection 
with resistant gram-positive organisms, and that its use is quite widespread. 
4.3.1 Effectiveness of topical antibiotic prophylaxis in spinal and cardiac procedures 
In one clinical study that highlighted the potential of local antibiotic prophylaxis, Rohde and 
colleagues reported and analyzed the incidence of spondylodiscitis after lumbar disc 
surgery in 1642 patients in a German center (Rohde et al., 1999).19 Postoperative 
spondylodiscitis is the result of intraoperative contamination and, theoretically, could be 
prevented with prophylactic antibiotics. The infection is considered rare, but the 
retrospective design of most existing studies and the scarce use of magnetic resonance 
imaging for early radiologic diagnosis suggest that the reported incidence rates may be 
underestimates. Of the 1642 patients, 508 were not given any prophylactic antibiotics, while 
in 1134 patients a collagenous sponge containing gentamicin was placed in the cleared disc 
space. In 19 of the 508 patients who were not treated with antibiotic prophylaxis (3.7%), a 
postoperative spondylodiscitis developed, whereas none of the 1134 patients who received 
antibiotic prophylaxis became symptomatic, demonstrating that antibiotic-containing 
sponges placed in the cleared disc space were effective in completely preventing 
postoperative spondylodiscitis. 
Local antibiotic prophylaxis of sternal wound infection was studied in a group of nearly 2000 
patients from two cardiothoracic centers in Sweden (Friberg et al., 2005). 20 The control group 
of 967 patients received routine systemic antibiotic prophylaxis with i.v. isoxazolyl-penicillin. 
The treatment group of 983, in addition to the same routine intravenous antibiotic prophylaxis, 
was also treated with a collagen sponge containing 260mg of Gentamicin, which was placed 
between the sternal halves before closure. The study end-point was any SWI identified at any 
time over the two-months postoperative follow-up. In total, 129 patients developed a SWI; 42 
(4.3%) in the treatment group and more than double -- 87 or 9.0% -- in the control group. In a 
similar study, 272 patients received a Gentamicin-collagen implant under the sternum before 
closure and 270 served as controls (Eklund et al., 2005).21 The incidence of SWI in the control 
group (5.9%) was 50% higher than in the treatment group (4.0 %). 
4.3.2 Infection rate-reducing potential of local antibiotic prophylaxis in cardiac, 
orthopaedic, and neurological surgery 
Because there are relatively few local antibiotic prophylaxis studies, but the results of 
existing trials are consistently promising, the current North American Spine Society 
                                                                          
18 Vander Salm TJ, Okike ON, Pasque MK, Pezzella AT, Lew R, Traina V, Mathieu R. “Reduction of 
sternal infection by application of topical vancomycin.” J Thorac Cardiovasc Surg 1989;98(4):618-22 
19 Rohde et al., “Spondylodiscitis after lumbar discectomy. Incidence and a proposal for prophylaxis.” 
Spine (Phila Pa 1976), 1998 Mar 1;23 (5):615-20. 
20 Friberg O, Svedjeholm R, Soderquist B, Granfeldt H, Vikerfors T, Kallman J. “Local gentamicin 
reduces sternal wound infections after cardiac surgery: a randomized controlled trial.” Ann Thorac Surg. 
2005;79(1):153-61 
21 Eklund, A.M., M. Valtonen, K.A. “Prophylaxis of sternal wound infections with gentamicin-
collagen implant: randomized controlled study in cardiac surgery.” Journal of Hospital Infection (2005) 
59, 108–112. 
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Guideline, American Academy of Orthopedic Surgeons Recommendations, and Society of 
Thoracic Surgeons Practice Guidelines suggest further research that would lead to a more 
thorough and conclusive assessment of the effectiveness of local antibiotic prophylaxis 
(Watters et al., 2007; AAOS 2010, Edwards et al., 2006; Endelman et al., 2007).  
5. Systemic and perioperative risk factors for postoperative osteomyelitis  
5.1 Infection risk factors in cardiac surgery 
Many systemic factors beyond the surgeon’s control increase the patients’ risk for soft tissue 
infection and osteomyelitis. In cardiac surgery, although surgeons vary in their operative 
treatment of complicated median sternotomy wounds (El Oakley, 1996), there is a 
considerable consensus, supported by multiple prospective clinical studies, that obesity 
stands out as one of the main predictors of poststernotomy wound complications and 
osteomyelitis of the sternum (Milano et al., 1995;22; Lamm et al., 1998;23 Losanoff et al., 2002; 
Szerafin et al., 1999). Szerafin and colleagues note the need to adjust the dose of antibiotic 
prophylaxis to the body weight to ensure effectiveness of this infection-preventing measure in 
obese patients (Szerafin et al., 1999). The incidence of infection of soft or osseous tissue in itself 
increases risk to patient, regardless of the patient's preoperative condition. Underscoring the 
importance of effective prophylaxis, Milano and colleagues found that postoperative interval 
mortality during the first 90 days after surgery for the patients with mediastinitis was double 
that of the patients without mediastinitis (11.8% compared with 5.5%); between 1 and 2 years 
after surgery interval mortality in the mediastinitis group was nearly four times the mortality 
reported for the non-mediastinitis patients (8.1% vs. 2.3%). Having reviewed professional 
literature and 13 other risk-evaluating studies, Milano prospectively collected data on 20 
preoperative and intraoperative variables on 6459 consecutive patients who underwent CABG 
and identified four highly significant independent predictors for the development of sternal 
dehiscence and mediastinitis (Milano et al., 1995). Losanoff and colleagues in their 
comprehensive review also analyzed identifiable risks that may serve as reliable predictors of 
sternal wound infection (Losanoff et al., 2002). 
 
 Obesity  
 Congestive heart failure   
 Previous heart surgery  
 Duration of the surgical procedure 
 Diabetes mellitus 
 Chronic obstructive airway disease 
 Smoking 
 Larger female breast size 
Table 1. Predictors of Deep Sternal Wound Infection: 
                                                                          
22 Carmelo A. Milano, MD; Karen Kesler, MS; Nancy Archibald, MHA, MBA; Daniel J. Sexton, MD; 
Robert H. Jones, MD. “Mediastinitis After Coronary Artery Bypass Graft Surgery.”Circulation. 
1995;92:2245-2251 doi: 10.1161/01.CIR.92.8.2245 
23 Lamm P., Gödje O.L., Lange T., Reichart B. “Reduction of wound healing problems after median 
sternotomy by use of retention sutures.” Ann Thorac Surg 1998;66:2125-2126 
www.intechopen.com
Management of Bone Bleeding During Surgery and 
Its Impact on the Incidence of Post-Operative Osteomyelitis 
 
161 
Milano’s study and his review of the relevant literature suggest that obesity and duration of 
surgery are the most important predictors of mediastinitis. Furthermore, his study 
documents for the first time that post-operative mediastinitis has a significant negative 
influence on long-term survival independent of the patient's preoperative condition. 
5.2 Infection risk factors in orthopedic and neurosurgical procedures 
Spinal and orthopedic surgery carries its own systemic risks (Kanafani et al., 2006).24 There 
are multiple factors, such as immunodeficiency, immunosuppression, diabetes, existing 
implants, malnutrition, and others, that may increase arthroplasty patient’s risk of 
bacteremia and hematogenous total join infection following an invasive procedure (AAOS, 
2010). A number of factors, including lymphopenia, duration of surgical procedure, and 
others, increase the risk of infection in spinal surgery patients (Kanafani et al., 2006; Watters 
et al., 2007). Given the potential adverse outcomes of joint and spinal infections -- both the 
human toll and the cost of treating spinal complications, infected joint replacements or 
infections – antibiotic prophylaxis is recommended in combination with patient risk 
assessment. 
 
 Existing prosthetic joint replacement 
 Immunocompromised/immunosuppressed patients 
 Inflammatory arthropathies (e.g.: rheumatoid arthritis, systemic lupus erythematosus) 
 Drug-induced immunosuppression 
 Radiation-induced immunosuppression 
 Presence of co-morbidities (e.g.: diabetes, obesity, HIV, smoking) 
 Previous prosthetic joint infections 
 Malnourishment 
 Hemophilia 
 HIV infection 
 Insulin-dependent (Type 1) diabetes 
 Malignancy 
 Megaprostheses 
 Lymphopenia 
 History of chronic infections 
Table 2. Risk Factors for Postoperative Hematogeneous or Direct-Inoculation Infection of the 
Spine or Joints25  
                                                                          
24 Kanafani ZA, Dakdouki GK, El-Dbouni O, Bawwab T, Kanj SS. “Surgical site infections following 
spinal surgery at a tertiary care center in Lebanon: incidence, microbiology, and risk factors.” Scand J 
Infect Dis. 2006;38(8):589-592. 
25 Compiled based on Kanafani et al. (2006), AAOS recommendations (revised 2010), and NASS 
Guidelines (2007)  
www.intechopen.com
 
Osteomyelitis 
 
162 
5.3 Excessive bleeding and duration of surgical procedure as infection risk factors 
Although cardiac patient’s weight and other health conditions at the time of the operation 
may be beyond the surgeon’s control, the duration of the surgical procedure depends, 
among other factors, on the management of bone and soft tissue bleeding (Samudrala, 2008). 
Similarly, in spinal and orthopedic surgery, the myriad systemic risks the patient brings into 
the operating room cannot be altered by the surgeon, but the duration of each procedure can 
– it is affected by clear visualization of the site of incision, which in turn depends on the 
management of bleeding.  
Both the spine and the sternum are highly vascular bones. Appropriate hemostasis methods 
significantly improve the visibility of the surgical site and therefore help shorten the time it 
takes to perform any given surgical procedure – and reduce the risks associated with the 
length of spinal or cardiac operations. 
6. Bone wax as a modifiable risk factor for osteomyelitis, inflammation, and 
inhibited bone healing  
6.1 Modifiable risk factors 
Risk factors for Osteomyelitis include a variety of systemic aspects ranging from cigarette 
smoking and malnutrition to immunosuppression, and osteoporosis, none of which can be 
controlled by the surgeon. However, risk factors under the surgeon’s control can also 
predispose a patient to surgical complications and Osteomyelitis. Careful reassessment of all 
known modifiable risk factors is necessary to help prevent the incidence of post-operative 
surgical site infections. Prevention is especially important given the prevalence of infections 
caused by antibiotic-resistant organisms. This reassessment of risk should include a careful 
look at the management of bone bleeding.  
6.2 Role of bone hemostasis materials in preventable complications 
Management of bone bleeding involves a decision about what to avoid and what to 
introduce into the operating site. But the choice of bone hemostasis material may also 
prove critical in determining the effectiveness of topical antibiotic prophylaxis. 
Researchers have isolated multiple systemic risk factors contributing to surgical site 
complications in procedures involving the bone, but the published clinical studies often 
do not mention the type of bone hemostasis material used in the trials, and consequently 
exclude them from perioperative risk assesments. And yet, some bone hemostats, such as 
bone wax, may by virtue of their properties and their very presence in the surgical wound 
increase the risk of complications (Szerafin et al, 1999).26 A foreign body introduced into 
the surgical site can become a nidus of infection, lead to chronic inflammation, and 
interfere with the bones’ reparative processes, thereby undermining any benefit antibiotic 
prophylaxis, especially topical applications, may have for the clinical outcome. 
                                                                          
26 Szerafin and colleagues link the absence of bone wax to reduced instances of mediastinitis: 
“Nontraumatic surgical techniques, with limited use of electrocautery and without applying bone wax, 
remain the most important factors in the prevention [of mediastinitis].” In: Szerafin Tamás, MD, Osama 
Jaber, MD, Árpád Péterffy, MD, PhD. “Reduction of wound healing problems after median sternotomy 
(letter to the editor).” Ann Thorac Surg 1999; 68: 2388. 
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6.2.1 Bone wax as bone hemostasis material 
Bone wax, composed of beeswax and softening agents, has been widely used for over one 
hundred years. Unadulterated beeswax was used for amputation hemostasis during the US 
Civil War. The development of modern softened bone wax has been attributed to Victor 
Horsley in 1892 (Horsley, 1892; Parker, 1892).27  
In the 1924 edition of Carson’s Modern Operative Surgery, the use of bone wax is 
recommended not for bone hemostasis – the currently prevalent application -- but for 
preventing bone healing and for the creation of a pseudoarthrosis (Verral, 1924).28 Since 
1924, there has not been a significant change in the formulation of bone wax. The material is 
still comprised of insoluble and non-resorbable beeswax softened with paraffin and/or 
isopropyl palmitate (Schonauer et al., 2004).29 Bone wax has no inherent hemostatic quality, 
and its effect on the bone remains consistent with Carson’s description.  
The material’s appeal is in its ease of use and its ability to effectively tamponade the 
vascular spaces in the bone, stopping bleeding immediately. Contrary to Carson’s 
recommendation, it is being used in procedures such as median sternotomy or spinal fusion, 
in which bone fusion and healing are required -- and in which pseudoarthrosis, or a failure 
of callus formation resulting in a non-osseous union of bone fragments, is the precise 
opposite of the desired surgical outcome. 
Although effective in stopping bone bleeding, bone wax has troublesome adverse effects. 
Once applied to the bone, the material remains at the surgical site indefinitely. It may 
become a nidus of infection and if contaminated, it may cause infection of the soft tissue or 
osteomyelitis (Allison, 1994; Chun et al., 1988; Finn et al., 1992; Gibbs et al., 2004; Johnson et 
al., 1981; Nelson et al., 1990; Wellisz et al., 2006, 2008a, 2008b). 
6.2.2 Inflammation and bone wax  
Bone wax remains at the site of application indefinitely and can cause giant cell formation as 
well as local inflammation of the surrounding tissue (Allison, 1994).30 Sorrenti et al. 
evaluated the reactions to bone wax in human tibias in 12 patients who had undergone tibial 
tubercle elevation. The patients underwent re-operation after 5 to 13 months, and bone 
biopsies were performed. A progressive reaction was described that began with a foreign 
body giant cell reaction with giant cells containing vacuoles filled with bone wax, to the 
formation of mature fibrous tissue. Reactions to bone wax consisted mainly of pain and 
swelling, often exacerbated by infection (Sorrenti, 1984).31 Alberius et al. utilized a rat 
                                                                          
27 Horsley, V. (1892). “Antiseptic wax [Letter].” Br Med J 1: 1165. Parker, R. (1892). “Aural pyaemia 
siccessfully treated by removing putrid thrombus of jugular vein and lateral sinus.” The British Medical 
Journal 1: 1076-1077 
28 Verrall, P. J. (1924). “Operation on Joints.” Modern Operative Surgery. H. W. Carson. London, Cassell & 
Co. . 1: 69. 
29 Schonauer C, Tessitore E, Barbagallo G, Albanese V, Moraci A. “The use of local agents: bone wax, 
gelatin, collagen, oxidized cellulose.” Eur Spine J. 2004;13 (suppl 1):S89–S96. 
30 Allison RT. “Foreign body reactions and an associated histological artefact due to bone wax.” Br J 
Biomed Sci 1994;51:14-7. 
31 Sorrenti SJ, Cumming WJ, Miller D. “Reaction of the human tibia to bone wax.” Clin Orthop Relat Res 
1984:293-6. 
www.intechopen.com
 
Osteomyelitis 
 
164 
calvarial bone model to identify the three stages of inflammatory reaction to bone wax: 1) a 
nonspecific inflammatory response; 2) a foreign body reaction; and 3) a marked fibrous 
reaction (Alberius et al., 1987).32 The observation is consistent with histologic findings 
associated with the implantation of bone wax in a rat tibia model, which typically include 
foreign-body reactions characterized by giant cells, plasma cells, fibrous tissue, and a lack of 
bone formation (Howard & Kelley, 1969). 33  
The inflammatory reactions to bone wax may also be a source of post-operative pain. A 
report from Norway described seven patients with intractable pain following the use of 
bone wax in foot surgery (Anfinsen et al., 1993).34 Five of the patients were pain-free after 
the bone containing the inflamed bone wax was resected. Anecdotal reports describing 
adverse inflammatory reactions to bone wax are also common (Allison 1994; Anfinsen et al. 
1993; Angelini et al., 1987; Ates et al., 2004; Aurelio et al., 1984; Bolger et al., 2005; Chun, et 
al., 1988; Cirak & Unal 2000; Hadeishi et al., 1995; Julsrud, 1980; Katz& Rootman, 1996; 
Kothbauer et al., 2001; Low & Sim 2002; Patel et al., 2000; Verborg et al., 2000; Wolvius & 
van der Wal 2003;).35 Reactions consist mainly of pain and swelling, often exacerbated by 
infection. 
6.2.3 Infection and bone wax 
There is evidence that bone wax not only remains at the surgical site indefinitely but also 
actually increases infection rates. Researchers Johnson and Fromm found that in a rabbit 
iliac crest defect model bone wax decreases the natural ability of bone to clear bacteria 
                                                                          
32 Alberius, P., B. Klinge, et al. (1987). “Effects of bone wax on rabbit cranial bone lesions.” J 
Craniomaxillofac Surg 15(2): 63-67. 
33 Howard TC, Kelley RR. “The effect of bone wax on the healing of experimental rat tibial lesions.” Clin 
Orthop Relat Res 1969; 63:226 –32. 
34 Anfinsen, O. G., B. Sudmann, et al. (1993). “Complications secondary to the use of standard bone wax 
in seven patients.” J Foot Ankle Surg 32(5): 505-508. 
35 See: Allison, 1994; Anfinsen et al. 1993; Angelini, el-Ghamari, et al. “Poststernotomy pseudo-arthrosis 
due to foreign body reaction to bone wax.” Eur J Cardiothorac Surg 1987; 1(2): 129-130.et al., 1987; Ates, O., 
S. R. Cayli, et al. 2004. “Bone wax can cause foreign body granuloma in the medulla oblongata.” Br J 
Neurosurg 2004; 18(5): 538-540. Aurelio, J., B. Chenail, et al. “Foreign-body reaction to bone wax. Report of a 
case.” Oral Surg Oral Med Oral Pathol 1984; 58(1): 98-100. Bolger WE, Tadros M, et al. “Endoscopic 
management of cerebrospinal fluid leak associated with the use of bone wax in skull-base surgery.” 
Otolaryngol Head Neck Surg 2005; 132(3): 418-420. Chun PK, Virmani R, et al. “Bone wax granuloma causing 
saphenous vein graft thrombosis.” Am Heart J 1988; 115(6): 1310-1313. et al., 1988; Cirak B & Unal O. 
“Iatrogenic quadriplegia and bone wax. Case illustration.” J Neurosurg 2000; 92(2 Suppl): 248.; Hadeishi H., 
N. Yasui, et al. (1995). “Mastoid canal and migrated bone wax in the sigmoid sinus: technical report.” 
Nurosurgery 1995; 36(6): 1220-1223; discussion 1223-1224;. Julsrud, ME (1980). “A surgical complication: 
allergic reaction to bone wax.” J Foot Surg 1980; 19(3): 152-154.Katz SE & Rootman J. “Adverse effects of 
bone wax in surgery of the orbit.” Ophthal Plast Reconstr Surg 1996; 12(2): 121-126., 1996; Kothbauer KF, 
Jallo GI, et al. “Foreign body reaction to hemostatic materials mimicking recurrent brain tumor. Report of 
three cases.” J Neurosurg 2001; 95(3): 503-506.; Low WK & Sim CS. “Bone wax foreign body granuloma in 
the mastoid.” ORL J Otorhinolaryngol Relat Spec 2002; 64(1): 38-40.; Patel RB et al. “Bone wax as a cause of 
foreign body granuloma in the cerebellopontine angle. Case illustration.” J Neurosurg 2000; 92(2): 362.; 
VerborgOK et al. “A retroperitoneal tumor a. s a late complication of the use of bone wax." Acta Orthop 
Belg2000; 66(4): 389-391.; Wolvius EB & van der Wal KG “Bone wax as a cause of a foreign body granuloma 
in a cranial defect: a case report.” Int J Oral Maxillofac Surg 2003; 32(6): 656-658.; 
www.intechopen.com
Management of Bone Bleeding During Surgery and 
Its Impact on the Incidence of Post-Operative Osteomyelitis 
 
165 
(Johnson & Fromm, 1981).36 In a rat tibia model, Nelson and colleagues observed that the 
presence of bone wax reduced the amount of Staphylococcus aureus needed to produce 
osteomyelitis by a factor of 10,000 (Nelson et al., 1990), a finding that is particularly alarming 
given the growing prevalence of the methicillin-resistant Staph. aureus. In a clinical study of 
spinal procedures conducted by Gibbs and colleagues, infection rates following spinal 
surgery increased ten-fold – 1 in 7 vs. 1 in 72 infections -- when bone wax was used for bone 
hemostasis (Gibbs et al., 2004).37 Similarly, researchers observed that bone wax increased the 
risk of mediastinitis following sternotomies performed during cardiac procedures (El 
Oakley, 1996; Fynn-Thompson et. al., 2004; Hollenbeak et. al., 2000; Losanoff et al., 2002; 
Szerafin et al., 1999).38 
6.2.4 Bone wax and bone healing 
The healing potential of bone, whether subject to trauma or surgery, is influenced by a 
variety of biochemical, biomechanical, cellular, hormonal, and pathological processes. The 
cellular components of bone consist of osteogenic precursor cells, osteoblasts, osteoclasts, 
osteocytes, and the hematopoietic elements of bone marrow, all of which are integral to new 
bone formation and regeneration. When applied to the cut or resected surface of the bone, 
whether sternal, vertebral, cranial, or other, traditional bone wax inhibits bone healing by 
interfering with the formation of new bone (osteogenesis).  
6.2.4.1 Bone wax and inhibition of new bone formation 
Living bone is in a constant state of bone deposition, resorption, and remodeling. This 
continuously occurring natural cycle of creation, destruction, and re-shaping of the osseous 
tissue is what facilitates the bone healing process (Kalfas, 2001).39 Bone wax not only 
compromises the bone’s ability to heal by increasing the risk of osteomyelitis (Gibbs et al., 
2004), but it also interferes with healing directly by disrupting the regenerative processes 
necessary to achieve an osseous fusion after surgery. 
Bone healing occurs in three distinct but overlapping stages: 1) the early inflammatory stage, 
when hematoma forms and granulation occurs; 2) the repair stage, in which cartilage and 
callus replace hematoma; and 3) the late remodeling stage, in which the bone regains its 
shape, circulation improves, and mechanical strength returns (Kalfas, 2001).  
The first 1 to 2 weeks are a period in which inflammation and revascularization occur. During 
the first few hours and days, inflammatory cells and fibroblasts infiltrate the bone, which 
results in the formation of granulation tissue, ingrowth of vascular tissue, and migration of 
mesenchymal cells. The mesenchymal cells then differentiate into osteoblasts and osteoclasts. 
                                                                          
36 Johnson P, Fromm D. “Effects of bone wax on bacterial clearance.” Surgery 1981;89:206- 209 
37 Gibbs L, Kakis A, Weinstein P, et al. “Bone wax as a risk factor for surgical-site infection following 
neurospinal surgery.” Infect Control Hosp Epidemiol 2004; 25:346Y348  
38 El Oakley RM, Wright JE. “Postoperative mediastinitis: classification and management.” Ann Thorac 
Surg 1996;61:1030-6. Fynn-Thompson F, Vander Salm TJ. “Methods for reduction of sternal wound 
infection.” Semin Thorac Cardiovasc Surg 2004;16:77-80. Hollenbeak CS, Murphy DM, Koenig S, 
Woodward RS, Dunagan WC, Fraser VJ. “The clinical and economic impact of deep chest surgical site 
infections following coronary artery bypass graft surgery.” Chest 2000;118:397-402. 
39 Kalfas, I.H., MD. “Principles of Bone Healing.” Neurosurg Focus 2001; 10 (4):Article 1, p. 7-10 
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Osteoblasts are mature, metabolically active bone forming cells, which arise from 
osteoprogenitor cells located in the deeper layer of periosteum and the bone marrow. They 
secrete osteoid, the unmineralized organic matrix that subsequently undergoes 
mineralization, giving the bone its strength and rigidity. As their bone forming activity 
nears completion, some osteoblasts are converted into osteocytes whereas others remain on 
the periosteal or endosteal surfaces of bone as lining cells. Osteoblasts also play a role in the 
activation of bone resorption by osteoclasts, setting the stage for later bone remodeling.40 
6.2.4.2 Bone wax and inhibition of bone fusion 
With the application of a thin layer of bone wax on a cut surface of the bone, even if bone 
wax has been applied and then scraped off, interference with bone healing occurs. A group 
of researchers demonstrated in 1969 that bone wax prevents bone healing in an animal 
model and concluded that bone wax is contraindicated in areas where bone fusion is desired 
(Howard & Kelley, 1969).41 In the clinical setting, autopsy studies have demonstrated 
persistent sternal nonunion attributed to the presence of bone wax (Sudman et al., 2006).42 
Sternal bone nonunion after cardiac surgery is almost always associated with concomitant 
mediastinitis (Losanoff et al., 2002; El Oakley & Wright, 1996). 
Sternal nonunion observed by Sudman and colleagues was accompanied by chronic 
inflammatory reactions with the presence of residual bone wax up to 10 years after median 
sternotomy procedure (Sudman et al., 2006). 
 
Fig. 1. Bone Wax Advantages and Complications 
Solheim and colleagues examined the properties of local hemostats for osseous tissue, 
assuming that, to be effective, the materials should be absorbable, biocompatible and should 
not inhibit osteogenesis. They evaluated different local hemostats by observing tissue 
response and effect on demineralized bone-induced heterotopic osteogenesis in the 
abdominal muscle of 120 rats. Non-absorbable bone wax of 88% beeswax and absorbable 
                                                                          
40 See: Copenhaver WM, Kelly DE, Wood RL: “The connective tissues: cartilage and bone,” in 
Copenhaver WM, Kelly DE, Wood RL (eds): Bailey’s Textbook of Histology, ed 17. Baltimore: Williams & 
Wilkins, 1978, pp 170–205; Recker RR: “Embryology, anatomy, and microstructure of bone,” in Coe FL, 
Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York: Raven, 1992, pp 219–240. 
41 Howard TC, Kelley RR. “The effect of bone wax on the healing of experimental rat tibial lesions.” Clin 
Orthop Relat Res 1969; 63:226 –32. 
42 Sudmann B, Bang G, Sudmann E. “Histologically verified bone wax (beeswax) granuloma after 
median sternotomy in 17 of 18 autopsy cases.” Pathology 2006; 38:138–41. 
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bovine fibrin-collagen paste both significantly inhibited osteoinduction, whereas a 
bioerodible polyorthoester drug delivery system with or without 4% gentamicin did not. 
Bone wax was not absorbed and induced a chronic foreign body reaction. Fibrin-collagen 
paste induced less inflammation with numerous monocytes and macrophages with 
engulfed material. Bioerodible polyorthoester caused a very moderate tissue reaction and 
was mostly resorbed after four weeks (Solheim et al., 1992). 43 
Despite its good handling and effectiveness in stopping bone bleeding instantly, the long-
term complications associated with the use of traditional bone wax far outweigh its 
usefulness as a bone hemostasis material. Although for its ease of use and effectiveness in 
surgery it remains the most commonly used bone hemostasis material, given its ties to 
widely reported complications, a variety of alternative bone bleeding management methods 
have been developed. 
7. Alternative bone hemostasis materials and methods 
7.1 Surgical technique and management of bone bleeding 
Management of bleeding is an integral aspect of the surgical technique. One of the options 
available to the surgeon operating on the osseous tissue is a mechanical barrier, such as that 
created by bone wax, which works to occlude bleeding from the open channels of the bone. 
In soft tissue hemostasis, surgeons most frequently chose electrocautery, a technique in 
which heat causes capillaries and small blood vessels to collapse and seal. Cushing first 
reported the use of this technique in 1921, after he used it in neurosurgical procedures. 
Electrocautery has since become a common hemostatic tool in modern surgery across all 
specialties, becoming a soft tissue corollary to bone wax. 
7.1.1 Electrocautery and bone hemostasis 
Electrocautery works through a pulsating (or intermittent) wave delivered to the surgical 
site by a unipolar device causing tissue dehydration and vessel thrombosis (Neumayer, 
2008). 44 Despite the structural differences between soft tissue and cut bone surfaces, 
electrocautery is commonly used for both. The thermal settings used to seal bleeding vessels 
are generally ineffective in stemming bleeding from open vascular channels in the bone. 
Higher heat settings can stop bone bleeding, but burning tissue to the sufficient degree for a 
charred coagulum physically to block blood flow damages osseous tissue, interferes with 
bone healing, and increases the incidence of postoperative infection. Excessive use of this 
technique for bone should be avoided. (El Oakley et al., 1996; Tang et al., 2004; Nelson et. al., 
1990; Nishida et al., 1991).45 
                                                                          
43 Solheim E, Pinholt EM, Bang G, Sudmann E. “Effect of local hemostatics on bone induction in rats: a 
comparative study of bone wax, fibrin-collagen paste, and bioerodible polyorthoester with and without 
gentamicin.” J Biomed Mater Res. 1992 Jun;26(6):791-800. 
44  Neumayer, L., Vargo, D. (2008) “Principles of Preoperative and Operative Surgery”, In:  Townsend: 
Sabiston Textbook of Surgery, 18th ed. Courtney M. Townsend Jr. R. Daniel Beauchamp B. Mark Evers, 
Kenneth L. Mattox, pp. (251-279), Saunders Elsevier, 978-1-4160-3675-3, Philadelphia, PA 
45 El Oakley RM, Wright JE. “Postoperative mediastinitis: classification and management.” Ann Thorac 
Surg 1996;61:1030-6. 
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7.1.2 Hemostasis through natural clotting 
Another approach to bone Hemostasis is to let the bone bleed throughout the surgery. In this 
way, the surgeon does not introduce any foreign materials into the site and allows the 
bleeding bone to clot naturally. However, research has shown that the risks of unnecessary 
bleeding include increased blood loss and the costs and multiple risks associated with blood 
transfusions (Rogers et al, 2009).46 Median sternotomies cause heavy bleeding, and complex 
spinal reconstructive procedures are invariably associated with excessive intraoperative blood 
loss, which significantly increases the risk of severe perioperative complications (Block, 
2005).47 Samudrala summarizes the benefits of effective hemostasis, which include decreased 
morbidity and mortality, fewer transfusions, reduced surgical time, better visualization of the 
surgical field – and, above all, better surgical outcome (Samudrala, 2008).48 
7.2 Topical bone hemostats 
7.2.1 Mechanical barrier 
Topical hemostatic agents are mechanical barriers routinely used to achieve hemostasis of 
cancellous bone surfaces during neurological, cardio-thoracic, orthopedic, maxillofacial, and 
a variety of other surgical procedures, including procurement of bone graft material from 
the iliac crest. A mechanical barrier works to occlude bleeding from the open channels of the 
bone, the way bone wax does. The topical hemostatic agents developed as an alternative to 
bone wax have various active ingredients and mechanisms of actions, thus affecting 
hemostasis and bone healing differently. 
7.2.2 Synthetic tamponade 
A common method of occluding bleeding used strictly for the vascular surface of cut or 
resected bone is a tamponade, which creates a physical barrier that stops blood flow by 
blocking osseous blood channels, the way bone wax does. Tamponade materials are 
beneficial to the surgeon by providing hemostasis that is both immediate and easy to apply. 
Products in this group are direct alternatives to bone wax and offer many of the same 
benefits, but not the risks. Physical barriers are applied directly to the bone, can be shaped to 
the surgeon’s needs and work immediately. While bone wax remains at the site of 
application indefinitely creating a host of problems, newer products made of water-soluble 
                                                                          
Nelson DR, Buxton TB, Luu QN, Rissing JP. “The promotional effect of bone wax on experimental 
Staphylococcus aureus osteomyelitis.” J Thorac Cardiovasc Surg 1990;99:977-80. 
Nishida H, Grooters RK, Soltanzadeh H, Thieman KC, Schneider RF, Kim WP. “Discriminate use of 
electrocautery on the median sternotomy incision. A 0.16% wound infection rate.” J Thorac Cardiovasc 
Surg 1991;101:488-94. 
Tang GH, Maganti M, Weisel RD, Borger MA. “Prevention and management of deep sternal wound 
infection.” Semin Thorac Cardiovasc Surg 2004;16:62-9. 
46 Rogers MA, Blumberg N, Saint S, Langa KM, Nallamothu BK. “Hospital variation in transfusion and 
infection after cardiac surgery: a cohort study.” BMC Med 2009;7:37. 
47 Block JE.. “Severe blood loss during spinal reconstructive procedures: the potential usefulness of 
topical hemostatic agents.” Med Hypotheses. 2005; 65(3):617-21 
48 Samudrala, S.. “Topical Hem static Agents in Surgery: A Surgeon’s Perspective.” AORN Journal, 2008. 
Supplement: Intraoperative Bleeding and Hemostasis in Surgical Procedures. vol. 88, no 3: p. S2-11 
www.intechopen.com
Management of Bone Bleeding During Surgery and 
Its Impact on the Incidence of Post-Operative Osteomyelitis 
 
169 
alkylene oxide copolymers (AOC) provide immediate hemostasis but remain at the site for 
less than 48 hours (Magyar et. al., 2008).49 These copolymers are inert, and they are 
eliminated from the body unmetabolized via the kidneys and liver. Recent research in 
animal models has shown that AOC based product does not increase infection rates, does 
not promote inflammation, and does not interfere with bone healing (Armstrong, 2010; 
Magyar et al., 2008; Sawan et al., 2010; Wellisz et al. 2006, 2008a, 2008b).50 An AOC based 
bone hemostasis material (Ostene®) has been available since 2006  and is currently 
distributed by Baxter International, Inc. 
7.3 Soft tissue hemostats  
Bleeding from bone can also be controlled with soft tissue hemostats. Soft tissue 
hemostasis materials can aid in the activation of the body’s natural clotting mechanism. 
Unlike bone wax, soft tissue hemostats are made from a range of resorbable ingredients. 
These ingredients, discussed more fully below, take anywhere from days to months to 
resorb. 
7.3.1 Gelatin 
Gelatin based agents are generally made from animal skin gelatin mixed and baked into a 
sponge, powder, or a film. These materials work by creating a physical matrix followed by 
swelling of the material to control bleeding. Gelatin sponges are non-absorbable and can 
expand up to 200% of their initial volume. If left in the wound, they may act as a nidus for 
infection and abscess formation (Lindstrom, 1956).51 Gelatin-based agents have also been 
reported to delay bone healing (Schonauer et al, 2004).52 
7.3.2 Thrombin 
Thrombin is derived from either bovine or human sources. It provides hemostasis in soft 
tissue by converting fibrinogen to fibrin to form clots and activate clotting factors. Thrombin 
                                                                          
49 Magyar CE, Aghaloo TL, Atti E, Tetradis S.“ Ostene, a new alkylene oxide copolymer bone hemostatic 
material, does not inhibit bone healing.” Neurosurgery 2008;63:373-8; discussion 8. 
50 Armstrong et al. BMC Surgery 2010, 10:37 http://www.biomedcentral.com/1471-2482/10/37., 
Magyar CE, Aghaloo TL, Atti E, Tetradis S. “Ostene, a new alkylene oxide copolymer bone hemostatic 
material, does not inhibit bone healing.” Neurosurgery 2008;63:373-8; discussion 8., Sawan A, Elhawary 
Y, Zaghlool Amer M, & Abdel Rahman M. “Controversial Role of Two Different Local Haemostatic 
Agents on Bone Healing.” Journal of American Science, 2010; 6(12):155-163]. (ISSN: 1545-1003., Wellisz T, 
Armstrong JK, Cambridge J, Fisher TC: “Ostene, a new water-soluble bone hemostasis agent.” J 
Craniofac Surg 17: 420-425, 2006. Wellisz T, An YH, Wen X, Kang Q, Hill CM, Armstrong JK. “Infection 
rates and healing using bone wax and a soluble polymer material.” Clin Orthop Relat Res 2008; 466:481-6. 
Wellisz T, Armstrong JK, Cambridge J, et al. “The effects of a soluble polymer and bone wax on sternal 
healing in an animal model.” Ann Thorac Surg 2008; 85:1776-80; 
51 Lindstrom, P.A., “Complications from the use of absorbable hemostatic sponges.” AMA Arch Surg. 
1956; Iss. 73, pp. 133-141 
52 Schonauer C, Tessitore E, Barbagallo G, Albanese V, Moraci A. “The use of local agents: bone wax, 
gelatin, collagen, oxidized cellulose.” Eur Spine J. 2004;13 (suppl 1):S89–S96.Shearwood McClelland III, 
“Postoperative intracranial neurosurgery infection rates in North America versus Europe: A systematic 
analysis.” Am J Infect Control 2008; 36:570-3 
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works quickly and is easy to use. However, bovine thrombin has been known to trigger 
immunologic reactions (Achneck et. al., 2010).53 
Thrombin is commonly mixed with a gelatin sponge for areas with heavier bleeding. This 
product is effective because the gelatin ingredient works as a physical matrix while the 
thrombin works within the clotting cascade. The issues associated with this product include 
swelling, and it needs contact with fibrinogen in order to work (Achneck et. al., 2010). 
7.3.3 Oxidized Regenerated Cellulose (ORC) 
Oxidized regenerated cellulose-based products are sold in sheets and act as a physical 
matrix that promotes the initiation of clotting. ORC also works by swelling and gel 
formation, as well as surface interactions with proteins, platelets and intrinsic and 
extrinsic pathway activation (Schonauer, 2004). The low PH of this product is shown to 
have an antimicrobial effect. However, the acidity may cause inflammation of surrounding 
tissue and interfere with healing (Tomizawa, 2005).54 ORC has also been shown to 
promote a foreign body reaction and reduce bone repair in rat studies (Geary & Frantz, 
1950; Ibarrola et al., 1985).55 
7.3.4 Collagen 
Microfibrillar Collagen is derived from bovine corium. It is available as flour, foam, and in 
sheets. These products work by initiating platelet adherence and activation of the clotting 
cascade. Though some proved promising in their ability to promote clotting in 
reconstructive spinal surgery (Block, 2005)56, collagen-based products are associated with 
infection and delayed bone healing (Armstrong et al., 2008). Inflammation and residual 
material upon resection at up to 90 days have been found by Barbolt et al. (2001) 57 and Ereth 
et al. (2008).58  
7.3.5 Fibrin 
 Fibrin sealants are made up of two parts, thrombin (human) and fibrinogen, that are 
combined at the time of surgery. They work by inducing platelet aggregation and initiating 
the clotting cascade when applied directly to bleeding bony sites. The fibrinogen determines 
                                                                          
53Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. “A comprehensive 
review of topical hemostatic agents: efficacy and recommendations for use.” Ann Surg 2010;251:217-28. 
54 Tomizawa Y. “Clinical benefits and risk analysis of topical hemostats: a review.” J Artif Organs 
2005;8:137-42. 
55 Geary JR, Kneeland Frantz V. “New absorbable hemostatic bone wax; experimental and clinical 
studies.” Ann Surg 1950;132:1128-37., Ibarrola JL, Bjorenson JE, Austin BP, Gerstein H. “Osseous 
reactions to three hemostatic agents.” J Endod 1985;11:75-83. 
56 Block JE..“Severe blood loss during spinal reconstructive procedures: the potential usefulness of 
topical hemostatic agents.” Med Hypotheses. 2005; 65(3):617-21 
57 Barbolt TA, Odin M, Leger M, Kangas L. “Pre-clinical subdural tissue reaction and absorption study 
of absorbable hemostatic devices.” Neurol Res 2001;23:537-42.  
58 Ereth MH, Schaff M, Ericson EF, Wetjen NM, Nuttall GA, Oliver WC, Jr. “Comparative safety and 
efficacy of topical hemostatic agents in a rat neurosurgical model.” Neurosurgery 2008;63:369-72; 
discussion 72. 
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the mechanical strength of the sealant, while the thrombin concentration determines the 
rapidity of the clot (Achneck et al., 2010).59 Fibrin sealants are most frequently used for soft 
tissue hemostasis, but they have also been used for bone bleeding control during osseous 
tissue repair. Fibrin sealants are often used as an adjunct to other hemostasis materials. 
7.3.6 Platelet Rich Plasma (PRP)  
Platelet rich plasma (PRP) that is derived from the patient is also used in surgery for bone 
hemostasis. PRP is derived from the patient’s own blood by separating red blood cells from 
the fibrin and plasma in a centrifuge. The plasma, which forms a gel, is applied where 
hemostasis is needed. This technique relies on growth factors that trigger early wound 
healing said to be present in the PRP. The true benefit for PRP in bone hemostasis has yet to 
be demonstrated (Griffin et al. 2008)60, and the technique has shown to be a markedly 
expensive bone hemostasis alternative. Moreover, like all the other soft tissue hemostats, 
platelet rich plasma cannot replicate the handling and immediate hemostasis effect of bone 
wax, which many topical bone hemostasis materials seek to offer. 
7.4 Topical bone hemostats – towards a comparative analysis 
Few comparative studies of topical bone hemostasis materials have been published to date. 
Although more research and clinical data would help the surgeons navigate the field of 
available alternatives to bone wax more effectively and assess their merits more thoroughly, 
a comparative analysis is beginning to emerge. Because bone healing and the risk of 
infection are the main complications associated with bone wax, in their comparative studies 
of management of bone bleeding alternatives, the researchers tend to focus on new bone 
formation and osteomyelitis without losing sight of the materials’ effectiveness as 
hemostats. 
7.4.1 Studies of new bone formation and healing with topical bone hemostats  
In 1992, Solheim and colleagues examined traditional bone wax, absorbable bovine fibrin-
collagen paste, and a bioerodible polyorthoester drug delivery system. They concluded that, 
of the three bone hemostatics under scrutiny, polyorthoester alone did not significantly 
inhibit osteoinduction and, after causing a very moderate tissue reaction, was mostly 
resorbed at the end of week four of the study (Solheim et al., 1992). 
In a 1992 comparative study, Finn and colleagues evaluated the potential for bone 
regeneration in the presence of four common hemostatic materials in a dog model in a 
manner that parallels iliac bone procurement in humans in oral and maxillofacial surgery. 
The agents compared were Avitene (microfibrillar collagen; Medchem Products, Inc, 
Woburn, MA); bone wax (beeswax with isopropyl palmitate; Ethicon, Inc, Somerville, NJ); 
Gelfoam (absorbable gelatin sponge; The Upjohn Company, Kalamazoo, MI); and Surgicel 
(oxidized regenerated cellulose; Johnson & Johnson Products, Inc, Patient Care Division, 
New Brunswick, NJ). Five surgical defects were created in each dog for placement of the 
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four materials; one defect served as an empty control site. After two month healing, 
radiographic and histologic examination showed new bone formation in the presence of 
Avitene, Surgicel, and Gelfoam. Residual material incorporated in bone, without foreign-body 
response, was noted in the Avitene and Gelfoam sites. Bone wax, however, showed an intense 
foreign-body reaction, characterized by giant cells, plasma cells, fibrous granulation tissue, and 
lack of bone reformation. On the basis of these initial findings, it was concluded that Surgicel, 
Avitene, and Gelfoam might be adequate hemostatic agents for use in iliac bone procurement, 
whereas the use of bone wax appears to be contraindicated (Finn et al, 1992).61 
In 2010, Sawan and colleagues compared the effect of bone wax and a water-soluble 
alkylene oxide copolymer (AOC) material on mandibular bone healing in a rabbit model. 
Sawan’s comparative study of 45 rabits was designed to assess the role of bone wax and the 
effectiveness of a new synthetic alternative bone hemostat in the context of oral and 
maxillofacial surgery. The animals were divided into three groups: bone wax and polymer 
groups and a hemostat-free group, which served as a control. A surgical bone defect was 
created in the anterior mandibular area. Alkylene oxide copolymer (AOC) hemostat-treated 
defects showed faster healing rate at the end of the first and second weeks than defects left 
untreated. The copolymer (AOC) disappeared from the surgical defect by the end of week 
one without any presence of inflammatory cells in the defect. In the bone wax group, the 
defects showed large empty vacuoles, representing bone wax remnants with inflammatory 
cells infiltration that interfered with bone healing. Study results showed that water soluble 
alkylene copolymer is a biodegradable material and that it does not interfere with bone 
healing. In contrast, bone wax proved to cause foreign body reaction, inhibiting bone 
healing (Sawan et al., 2010). 
Two studies of topical bone hemostats conducted by Wellisz and colleagues in 2006 and 
2008 compared the effect of non-resorbable traditional bone wax and water-soluble alkylene 
oxide copolymer (AOC) on sternal bone healing and cranial bone healing respectively in an 
animal model. After six weeks, the results of the sternal healing study involving 20 rabbits 
showed normal bone healing in the polymer-treated group and nonunion with fibrotic scar 
tissue and the absence of new bone formation in the bone wax group. While the bone 
hemostasis was immediate and comparable for both materials, the application of the 
polymer hemostatic material to the sternum resulted in significantly stronger union 
compared with the use of bone wax. Comparative cranial bone healing by Wellisz and 
colleagues assessing bone healing with bone wax and AOC in a group of 24 rabbits 
produced similar results (Wellisz et al., 2006, 2008a). 
In a recent study, Armstrong and colleagues compared the effect of a water-soluble alkylene 
oxide copolymer (AOC) to oxidized regenerated cellulose (ORC) and microfibrillar collagen 
(MFC) on early bone healing in a rabbit tibia model with 12 animals. A group with no 
hemostatic material at all served as the control. Hemostasis was immediate after application 
of MFC and AOC, after 1-2 minutes with ORC, and >5 minutes for control. At 17 days post-
surgery, micro-CT analysis showed near-complete healing in control and AOC groups, 
partial healing in the ORC group, and minimal healing in the MFC group. Fractional bone 
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volume was 8 fold greater in the control and AOC groups than in the MFC group and over 
1.5-fold greater than in the ORC group. MFC remained at the application site with minimal 
healing at the defect margins and early fibrotic tissue within the defect. ORC-treated defects 
showed partial healing but with early fibrotic tissue in the marrow space. Conversely, 
control and AOC treated defects demonstrated newly formed woven bone rich in cellular 
activity with no evidence of AOC remaining at the application site. Armstrong and 
colleagues concluded that early healing appeared to be impaired by the presence of MFC 
and impeded by the presence of ORC. In contrast, AOC did not inhibit bone healing and 
may be a better bone hemostatic material for procedures where bony fusion is critical and 
immediate bone hemostasis required (Armstrong et al., 2010). 
 
Fig. 2. Representative micro-CT images of excised rabbit tibiae at 17 days post-surgery. Left 
column: Cross-section views through the center of the defect showing newly formed bone as 
slightly opaque in untreated (control), alkylene oxide copolymer- and oxidized regenerated 
cellulose-treated defects, and an absence of opacity in microfibrillar collagen-treated defects 
(bar = 5.0 mm). Center and right columns: micro-CT generated binarized images of 
mineralized tissue of the defect area (center) and area analyzed within the defect (right). 
AOC-treated and untreated (control) defects show substantial, well developed mineralized 
tissue, ORC-treated defect shows a more diffuse structure of mineralized tissue, and minimal 
mineralized tissue is observed within the MFC-treated defect. (Armstrong et al., 2010) 
www.intechopen.com
Management of Bone Bleeding During Surgery and 
Its Impact on the Incidence of Post-Operative Osteomyelitis 
 
175 
7.4.2 Studies of osteomyelitis with topical bone hemostats 
A 2008 comparative study assessing infection rates and healing in bone wax and AOC 
polymer treated bones with no treatment group as a control was designed to compare the 
two materials in a contaminated environment in a rabbit tibia defect model involving 24 
animals. Bone defects were treated with the two topical bone hemostasis materials and then 
subject to a bacterial challenge by inoculation with Staphylococcus aureus. After 4 weeks, 
100% of defects in the bone wax group became infected and developed osteomyelitis; none 
had evidence of bone healing. In the AOC polymer group and control group, 25% of defects 
developed osteomyelitis. The remaining 75% of defects in the polymer and control groups 
cleared the bacteria, showed no signs of osteomyelitis, and exhibited normal bone healing. 
The polymer-treated defects had a considerably lower rate of post-operative osteomyelitis 
and positive bone cultures compared with the bone wax-treated group. Wellisz and 
colleagues determined that there were no differences between the AOC polymer-treated 
group and control group in the rates of osteomyelitis, positive cultures, or bone healing, 
concluding that AOC may be a good alternative to bone wax when the risk of infection and 
bone healing are a concern (Wellisz et al., 2008b). 
7.4.3 Studies of effective bleeding management with topical bone hemostats  
In 2005, Block assessed the clinical effectiveness of several approaches to bone bleeding 
management in the context of complex spinal reconstructive procedures associated with 
excessive blood loss – the perioperative hemorrhage may be equivalent to estimated total 
blood volume, which significantly increases the risk of severe post-operative complications. 
Since highly vascular and widely exposed bony surfaces are not amenable to standard 
hemostatic maneuvers effective during soft tissue surgery, Block hypothesizes that 
underappreciated topical hemostatic agents may provide benefit by reducing the need for 
autologous predonation, banked donor blood, or antifibrinolytic agents. Topical agents Block 
evaluated -- combining collagen, thrombin and fibrin -- have demonstrated initial promise by 
inducing platelet aggregation and initiating the clotting cascade when applied directly to 
bleeding bony sites. Block’s conclusion: clinical studies are clearly warranted (Block, 2005). 
8. Redefining the management of bone bleeding: osteomyelitis, bone healing, 
and topical therapeutics 
More clinical studies evaluating the merits of next generation bone hemostasis materials – 
their handling, biocompatibility, safety, and effectiveness – are indeed warranted. Further 
research of the effectiveness of a wide range of existing alternatives to bone wax would help 
surgeons assess the properties and best use of all the available bone hemostasis options. It 
would open the way to using the management of bone bleeding as a tool to control blood 
loss and, at the same time, reduce the risk of post-operative infection, both of the soft tissue 
and osteomyelitis. 
8.1 Management of bone bleeding and topical therapeutics 
Topical use of anti-microbial agents applied to the cut sternum or vertebrae during surgery 
already shows promise in helping lower the incidence of post-operative osteomyelitis and 
soft tissue infection (Eklund, 2005; Friberg, 2005; Rohde, 1999). 
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Some of the newly available synthetic materials designed to control bone bleeding in 
surgery may be able to expand the repertoire of choices available to surgeons during various 
surgical procedures without increasing risk to patients. Topical bone hemostasis agents in 
particular have the potential to redefine the management of bone bleeding and reduce the 
risk of post-operative complications, including osteomyelitis, by combining the application 
of bone hemostats with the delivery of therapeutics directly to the cut bone. 
8.2 Osteomyelitis prevention and topical bone hemostasis with antibiotics 
A soluble bone hemostasis material that is easy to handle, stops bleeding by mechanical 
occlusion, and does not inhibit osteogenesis or increase the risk of infection, may be mixed 
with antibiotics and used for local prophylaxis during and immediately after surgery. Such 
a formulation would retain the carrier’s hemostatic properties to help manage bone bleeding 
and also allow for a controlled release of antibiotic of choice into the wound to prevent post-
operative infection of the bone (osteomyelitis) or the surrounding tissue. The compound 
could be used during any surgical procedure – orthopedic, maxillofacial, neurological, or 
cardiac -- that involves the cutting of bone. If the existing studies of local antibiotic 
prophylaxis are any guide, antimicrobial bone hemostats used as an adjunct to systemic 
infection-preventing measures could reduce the risk of osteomyelitis at least by half. 
8.3 Bone healing and topical bone hemostasis with bone growth factors 
An analogous formulation combining bone hemostatic properties with bone growth factors 
could be used to deliver bone graft material to resected bone, whether in spinal fusion, 
repair of infected arthroplasty, or in the course of major reconstructive procedure following 
sternal wound debridement and removal of foreign materials during the treatment of deep 
mediastinitis. Bone graft delivered to the surgical site with topical bone hemostasis material 
as a carrier would be both osteoinductive and hemostatic, osteoconductive and easily 
moldable. Management of bone bleeding which incorporates bone hemostasis into the larger 
surgical procedure could simplify the operation, help reduce risk, and improve clinical 
outcome. 
9. Conclusion 
The choice of bone hemostasis material is a modifiable but widely overlooked post-
operative infection risk factor, and proper management of bone bleeding may help reduce 
that risk. As a foreign body introduced during surgery into the wound, the bone hemostasis 
material can become a nidus of a surgical site infection. Traditional bone wax, in particular, 
illustrates this point. Despite its good handling and proven effectiveness, it inhibits bone 
healing and increases the risk of osteomyelitis across surgical procedures. Although great 
advances have been made in the use of antibiotic prophylaxis to reduce surgical wound 
complications, a better understanding of the impact of bone hemostasis technique and 
material choice on healing may help reduce infections and the rate of osteomyelitis even 
further, improving clinical outcomes. The possibility of combining topical bone hemostasis 
materials with therapeutics, such as antibiotics or bone grafts, may in the future broaden the 
repertoire of medical tools available to surgeons and redefine the role the management of 
bone bleeding could play in the prevention and treatment of osteomyelitis. 
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